GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acceleron Pharma Inc (NAS:XLRN) » Definitions » Change In Other Working Capital

Acceleron Pharma (Acceleron Pharma) Change In Other Working Capital : $-0.4 Mil (TTM As of Sep. 2021)


View and export this data going back to 2013. Start your Free Trial

What is Acceleron Pharma Change In Other Working Capital?

Acceleron Pharma's Change In Other Working Capital for the quarter that ended in Sep. 2021 was $-0.1 Mil. It means Acceleron Pharma's Other Working Capital declined by $0.1 Mil from Jun. 2021 to Sep. 2021 .

Acceleron Pharma's Change In Other Working Capital for the fiscal year that ended in Dec. 2020 was $-0.4 Mil. It means Acceleron Pharma's Other Working Capital declined by $0.4 Mil from Dec. 2019 to Dec. 2020 .

Acceleron Pharma Change In Other Working Capital Historical Data

The historical data trend for Acceleron Pharma's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acceleron Pharma Change In Other Working Capital Chart

Acceleron Pharma Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.65 -0.31 0.67 -0.21 -0.37

Acceleron Pharma Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.10 -0.08 -0.09 -0.12

Acceleron Pharma Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acceleron Pharma Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Acceleron Pharma's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Acceleron Pharma (Acceleron Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acceleron Pharma Inc (NAS:XLRN) » Definitions » Change In Other Working Capital
Comparable Companies
RETA UTHR MYOK ZLAB ADPT IOVA JAZZ ALLO MRTX FTSV OCSE:NOVO B ASX:CSL VRTX REGN XKRX:207940 SGEN MRNA ALXN XKRX:068270 INCY
Traded in Other Exchanges
N/A
Address
128 Sidney Street, Cambridge, MA, USA, 02139
Website
http://www.acceleronpharma.com
Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.
Executives
Sujay Kango officer: EVP, Chief Commercial Officer 1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Kevin F Mclaughlin officer: SVP, CFO and Treasurer C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Adam M Veness officer: SVP, General Counsel and Sec. C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Thomas A Mccourt director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
Habib J Dable director, officer: CEO and President C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Terrence C Kearney director IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Bristol Myers Squibb Co 10 percent owner 430 E. 29TH STREET 14 FLOOR NEW YORK NY 10016
Celgene Corp /de/ 10 percent owner 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Hite director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Jean George director CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Kemal Malik director C/O ACCELERON PHARMA INC. 128 SIDNEY STREET CAMBRIDGE MA 02139